UNISOUND (09678) releases the industry's first professional large-scale model "U2-Med Triple Medical Model" for the medical, medical insurance (including commercial insurance), and pharmaceutical fields.

UNISOUND (09678) announced that recently, based on the U2 pedestal model, the company has completed the iteration and upgrade of a large medical model and officially launched the industry's first professional large model "U2-Med Three Medical Model" (this upgrade) targeting the medical, medical insurance (including commercial insurance), and pharmaceutical fields. This upgrade further solidifies the company's model capabilities in the professional field, continuously advancing the technological iteration of high-value token scenarios. The model is expected to be widely embedded in the core processes related to the digital collaboration of the three medical fields, helping the company to accelerate the expansion of its large model business and generate long-term and sustainable revenue contributions. With the company's U2 large model pedestal, U2-Med has achieved significant improvements in computing efficiency and intelligent execution capabilities. As the industry's first industrial-grade large model integrating the full chain capabilities of the "three medicals," U2-Med integrates the company's ten years of deep expertise in the medical field, breaking the data and business silos of medical, medical insurance, and pharmaceuticals. It supports the digital transformation of the three medicals through integrated capabilities, covering a wide range of professional task scenarios in the medical field. U2-Med delves into the core business processes of the three medicals, bringing tangible capabilities and efficiency improvements to clinical doctors, insurance professionals, and pharmaceutical professionals: for doctors, the model has the ability to assist in diagnosis and treatment, generate medical records, identify clinical and electronic record risks, etc. For medical insurance and commercial insurance, the model can accurately identify overuse of medications, duplicate charges, excessive diagnostics, etc., support DRG/DIP compliance checks, help audit personnel focus on key checks; for the pharmaceutical industry, the model assists in pre-screening of subjects, verification of indications and contraindications, risk prompts for combined medication, etc. This upgrade truly realizes the intelligent collaboration of "clinical diagnosis and treatmentmedical insurance paymentmedical supply" in the three medicals, solving the core pain points of low cross-domain collaboration efficiency, fragmented control, and high labor costs in the industry in a one-stop manner. In the MedBench evaluation in July 2026, the U2-Med series models ranked first in both the full mode large models and intelligent agents. It also led in the "three medical comprehensive benchmark" for real business scenarios, with a non-thought mode comprehensive score of 89.1 and a thought mode score of 88.9, including medical record generation and quality control 93.3, post-diagnosis and medication management 94.1, and medical insurance and commercial insurance tasks 88.8. The evaluation data fully demonstrate that U2-Med is not just a general medical theoretical model, but a commercial-grade professional model that adapts to real business processes, with its technological capabilities directly converted into industrial value. After this upgrade, U2-Med will be deeply embedded in a wider range of three medical domains, using "expert-level" capabilities to create higher industrial value, while replacing repetitive work and unleashing the professional potential of three medical professionals. The company will continue to promote its large-scale landing in the three medical fields, accelerate the positive cycle of industrial data accumulation and model iteration, continuously strengthen its business barriers, and inject long-term momentum for the continuous release and commercial realization of high-value tokens. The company firmly believes that technological evolution will always follow the path of universal benefit; the ultimate vision of AGI lies in safeguarding and enhancing the well-being of the broader population. This is the initial intention of the company's more than ten years of deep cultivation in the medical fieldto transform cutting-edge intelligence into the core driving force for safeguarding Hangzhou Minsheng Healthcare and empowering industrial upgrades, and to practice the value concept of "intelligent benevolence" with the power of "intelligent progress."